Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer’s disease. The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer’s disease. Newt’s guest is Dr. Marwan Sabbagh, MD. He is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.
See omnystudio.com/listener for privacy information.
Episode 584: Treasury Secretary Yellen’s Visit to China
Episode 583: Founding Fathers – Alexander Hamilton
Episode 582: Founding Fathers – John Hancock
Episode 581: Founding Fathers – Samuel Adams
Episode 580: Founding Fathers – Benjamin Franklin
Episode 579: Founding Fathers – James Madison
Episode 578: Founding Fathers – Thomas Jefferson
Episode 577: Founding Fathers – John Adams
Episode 576: Founding Fathers – George Washington
Episode 575: Secretary Blinken’s Visit to China
Episode 574: The State of the Economy: UBS, Credit Suisse, and is Gold the Answer to Volatility?
Episode 573: Hunter Biden’s Plea Deal
Episode 572: Jason Chaffetz on “The Puppeteers”
Episode 571: Alex Soros Takes Over
Episode 570: Donald J. Trump and the Future of America
Episode 569: Jesse Kelly on “The Anti-Communist Manifesto”
Episode 568: The Fall of the FBI
Episode 567: Newt Gingrich on “March to the Majority”
Episode 566: D-Day and President Roosevelt’s Prayer
Episode 565: Fun Things to Do at Smithsonian’s National Zoo
Create your
podcast in
minutes
It is Free